Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (I
A newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that stimulating cancer makes them more visible to the body’s de
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.